Answers are grounded in this paper and cite their sources.
Background Neuroinflammation is implicated as a driver of cellular dysfunction in Alzheimer's disease (AD), yet there are currently no FDA-approved drugs to treat this pathology. Network models of protein-protein interactions (PPI) show promise in identifying drug mechanisms of action targeted towards disease pathologies. Objective We sought to identify repurposable drugs to treat neuroinflammation by screening drug targets on an extensive PPI network against proteins involved in AD neuroinflammatory pathways. Methods We identified 133 immune system pathway genes from AD genomic and transcriptomic studies, creating a network module on a human PPI network. We assessed the network proximity of this module to drug target modules across three screenings: inflammation-targeted drugs with a negative AD clinical trial, repurposed compounds in AD clinical trials as of 2025, and 1700 FDA-approved compounds. Drugs were prioritized if they had Z-scored proximity less than −2.0, a false-discovery rate corrected p -value less than 0.05, and evidence in transgenic mouse models or AD clinical trials. Results We found that anti-inflammatory drugs with negative AD clinical trials had low proximity to AD-neuroinflammatory targets, while the phase 2 drug baricitinib was significantly proximal. Screening 1700 FDA-approved compounds, we found 15 with significant network proximity to AD-immune system targets. Notably, cabozantinib, plerixafor, and bevacizumab had positive biomarker effects in AD mouse models. Conclusions We provide an in-silico line of evidence for several repurposable drugs to be tested further in-vitro and in-vivo studies of AD.
No takes yet. Share an insight, caveat, or question.
Cammann et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: